Regeneron to Acquire 23andMe for $256 Million in Bankruptcy Auction

George D. Yancopoulos, M.D., Ph.D., Co-Founder, Co-Chairman of the Board, President, and Chief Scientific Officer of Regeneron, stated:"Regeneron was one of the first biotechnology companies to bet its future on the power of DNA, driving our drug discovery efforts to deliver some of the world’s leading and most innovative medicines, including preventing blindness, treating allergic conditions (from asthma to atopic dermatitis), treating various forms of cancer, and even addressing Ebola and COVID-19. We have extensive experience in large-scale data management, collaborating with partners worldwide to link nearly 3 million consented participants’ DNA sequences with electronic health records, securely and reliably enabling future medical advancements. We believe we can help 23andMe achieve and solidify its mission to assist those interested in understanding their DNA and how to improve personal health, while further advancing Regeneron's use of large-scale genetic research to enhance society’s overall approach to treating and preventing diseases."

Regeneron intends to ensure compliance with 23andMe's consumer privacy policy and applicable laws regarding customer data processing. As the winning bidder, Regeneron is prepared to detail the intended use of customer data as well as existing privacy programs and security controls for review by the court-appointed independent customer privacy monitor and other stakeholders.

Aris Baras, M.D., Senior Vice President and Head of Regeneron Genetics Center®, stated:"23andMe is a pioneer in consumer genetics and research, and we are excited to have the opportunity to support their important mission of growing their platform and business. As a world leader in human genetics, the Regeneron Genetics Center is committed to safeguarding the genetic data of people globally and, with their consent, using that data for discoveries that benefit science and society. We assure 23andMe customers that we are dedicated to protecting the 23andMe dataset with high standards of data privacy, security, and ethical oversight, while fully realizing its potential to improve human health. Since 2013, the Regeneron Genetics Center has sequenced the genetic information of nearly 3 million people in its research, utilizing this de-identified data to make meaningful discoveries rapidly and at scale. We share a founding vision with 23andMe regarding the power of genetics and data and the health benefits for individuals and society in understanding the human genome. We believe we are well-suited to be responsible and effective stewards of 23andMe’s future, and we look forward to welcoming their talented team."

23andMe to Operate as a Wholly-Owned Direct or Indirect Subsidiary of Regeneron and Continue in Personal Genomics Services. Regeneron’s Acquisition Does Not Include 23andMe's Lemonaid Health Business. More Details on the Company’s Operational Plans Will Be Announced Upon Completion of the Transaction.

23andMe Interim CEO Joe Selsavage said:"We are pleased to have reached an agreement with a science-focused partner who will uphold our team and help advance our mission. With the support of Regeneron and their extensive experience in gene sequencing, testing, and discovery, we look forward to continuing to help people access and understand the human genome for the benefit of customers and patients."